| Species |
Human |
| Protein Construction |
CCL21 (Ser24-Pro134)
Accession # O00585 |
|
| Purity |
> 97% as analyzed by SDS-PAGE
> 97% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human lymphocytes is in a concentration range of 10.0-100.0 ng/ml. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
12.2 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.4, 150 mM NaCl. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Exodus-2/CCL21 is a novel CC chemokine discovered independently by three groups from the EST database, and shows 21-33% identity to other CC chemokines. Exodus-2 contains the four conserved cysteines characteristic of β chemokines plus two additional cysteines in its unusually long carboxyl terminal domain. It is expressed in lymph nodes of certain endothelial cells, and in the spleen and appendix. Exodus-2 chemoattracts T and B lymphocytes and inhibits hematopoiesis. |
| Synonyms |
6Ckine; CKb9; ECL; SCYA21; SLC; TCA4; C-C motif chemokine ligand 21 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
